Toggle navigation
PathBank
Browse
Pathways
Table of Primary Pathways
Compounds
Proteins
Search
Advanced Text Search
ChemQuery Structure Search
Molecular Weight Search
Sequence Search
Analyze
Over-Representation Analysis
Path-MAP Analysis
Pathway Enrichment Analysis
About
About PathBank
Statistics
Style Guide
Other Databases
Pathway Legend
Pathway Category Definitions
PathWhiz
Downloads
Contact Us
Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loading Pathway...
Error: Pathway image not found.
D(2) dopamine
receptor
D(4) dopamine
receptor
Voltage-
dependent
P/Q-type
calcium channel
subunit
alpha-1A
Voltage-
dependent
L-type calcium
channel subunit
beta-1
Voltage-
dependent
calcium channel
subunit
alpha-2/delta-2
Solute carrier
family 22
member 5
Sodium-
dependent
dopamine
transporter
Solute carrier
family 22
member 5
Synaptic
vesicular amine
transporter
Aromatic-L-
amino-acid
decarboxylase
Tyrosine
3-monooxygenase
Guanine
nucleotide-
binding protein
G(s) subunit
alpha isoforms
short
Dopamine
Aripiprazole
Aripiprazole
Ca
+
Ca
+
Dopamine
Aripiprazole
Aripiprazole
Dopamine
L-Dopa
CO
2
L-Tyrosine
Tetrahydrobiopterin
O
2
Dihydrobiopterin
H
2
O
Na
+
Na
+
Pyridoxal
5'-phosphate
GDP
Gi signaling
cascade
Fe2+
Cytosol
Postsynaptic Neuron
Presynaptic Neuron
Cytosol
Synaptic Vesicle
Synapse
Norepinephrine is
synthesized and stored in
synaptic vesicles at the
nerve terminal
Aripiprazole is a partial
agonist at D2 receptor. It
competes with the endogenous
dopamine for this receptor
but only has partial
efficacy when it binds to
this receptor, thus reducing
dopamine signaling
↓ Positive, negative and
cognitive symptoms of
schizophrenia
Aripiprazole will act as a
functional antagonist in
areas of high dopamine, such
as the mesolimbic pathway
Aripiprazole has a high
affinity for D2, D3
receptors and moderate
affinity for D4 receptors
Brain
Mesolimbic pathway
Aripiprazole is non
functional in the
nigrostriatal and
tuberoinfundibular pathways
Blood vessel - blood brain
barrier
Aripiprazole is taken orally
and absorbed from the
gastrointestinal tract.
DRD2
DRD4
CACNA1A
CACNB1
CACNA2D2
SLC22A5
SLC6A3
SLC22A5
SLC18A2
DDC
TH
GNAS
Dopamine
Aripiprazole
Aripiprazole
Calcium
Calcium
Dopamine
Aripiprazole
Aripiprazole
Dopamine
L-Dopa
Carbon dioxide
L-Tyrosine
Tetrahydrobiopterin
Oxygen
Dihydrobiopterin
Water
Sodium
Sodium
Guanosine
diphosphate
Gi signaling
cascade
DRD2
DRD4
CACNA1A
CACNB1
CACNA2D2
SLC22A5
SLC6A3
SLC22A5
SLC18A2
DDC
TH
GNAS
LDP
Abilify
Abilify
Ca
+
Ca
+
LDP
Abilify
Abilify
LDP
L-Dopa
CO
2
Tyr
BH4
O
2
BH3
H
2
O
Na
+
Na
+
Pyr-5'P
GDP
Gi si c
Fe2+
Cytosol
Postsynaptic Neuron
Presynaptic Neuron
Cytosol
Synaptic Vesicle
Synapse
Norepinephrine is
synthesized and stored in
synaptic vesicles at the
nerve terminal
Aripiprazole is a partial
agonist at D2 receptor. It
competes with the endogenous
dopamine for this receptor
but only has partial
efficacy when it binds to
this receptor, thus reducing
dopamine signaling
↓ Positive, negative and
cognitive symptoms of
schizophrenia
Aripiprazole will act as a
functional antagonist in
areas of high dopamine, such
as the mesolimbic pathway
Aripiprazole has a high
affinity for D2, D3
receptors and moderate
affinity for D4 receptors
Brain
Mesolimbic pathway
Aripiprazole is non
functional in the
nigrostriatal and
tuberoinfundibular pathways
Blood vessel - blood brain
barrier
Aripiprazole is taken orally
and absorbed from the
gastrointestinal tract.